Matthew Herper on Muck Rack

Matthew Herper

New York
Senior Editor — Forbes
As seen in: Forbes

Forbes reporter covering science and medicine

A Biotech's Depression Drug Returns From Dead, Setting Up Test For FDA — In January, Alkermes, a Waltham, Mass.-based biotechnology firm, announced that its experimental antidepressant, code-named ALKS 5461, had failed in two different clinical trials. Shares in the company fell from $60 to $33. Today, Alkermes announced that a third study of the drug had succeeded, leading shares to jump 43% in [...]

IBM To Build Life Sciences Supercomputer — IBM is building a $27 million supercomputer for the Korea Institute of Science, Technology and Information. The deal is one of IBM's biggest ever in life sciences supercomputing. For IBM , the machine may represent a significant win. It will be used primarily for life sciences research.

White House To Announce Big Push For Cancer Blood Tests — Vice President Joe Biden pauses as he speaks at the Cancer Moonshot Summit at Howard University in Washington, Wednesday, June 29, 2016. Biden is trying to bolster efforts to cure cancer at this summit focusing on research and innovative trials. (AP Photo/Carolyn Kaster) The White House, as part of the Cancer [...]

Hedge Fund Investor Sues Theranos For Lying 'Knowingly And Repeatedly' — Until now, there has been one big reason to believe that Theranos, the controversial diagnostics startup, could survive despite widespread doubts about whether its technology, which the company once promised would revolutionize the blood testing business, even works: its investors, after putting $700 million into the startup, seemed solidly behind Theranos and [...]

Antipsychotic Prescribed As Sleeping Pill — When AstraZeneca introduced the schizophrenia drug Seroquel in 1997, it was a dud. The London-based drug giant had no experience selling psychiatric drugs, and its then small sales force couldn't compete with the might of Eli Lilly and Johnson & Johnson , which ruled the market for antipsychotic medicines.

Bristol's Opdivo Disappoints in Lung Cancer, While Merck's Keytruda Surprises — FindTheCompany | Graphiq Shares of Bristol-Myers Squibb have fallen 26% since August, when a large study of lung cancer patients failed to demonstrate that its breakthrough cancer drug, Opdivo, could slow tumor growth or extend patients' lives better than existing chemotherapies. The full results of that study are out this morning, presented [...]

Bad Blood: The Decline And Fall Of Elizabeth Holmes And Theranos — Photo: Ethan Pines,, Forbes, Shutterstock. Design: Nick DeSantis, Forbes Staff Elizabeth Holmes-and her company, Theranos-promised to change the way people got blood tests, replacing needles with finger pricks. In June, FORBES' estimate of her net worth fell from $4.5 billion to $0. On October 5, Theranos got out of the [...]

Theranos: In Healthcare Most Good Ideas Don't Work — "In tech investors bet on people. Healthcare is different. In healthcare most great ideas don't work." Quoting myself seems a little odd, but that's where I landed yesterday after looking back on my two on-stage interviews with Theranos founder and chief executive Elizabeth Holmes. The main point of this post is [...]

Theranos Becomes A Shadow Of Its Imagined Self — Elizabeth Holmes at the Forbes Healthcare Summit last December. Last night laboratory testing business Theranos announced that it would lay off 340 people, or 43% of its workforce, and get out of the business of administering blood tests -- a business which has drawn the scrutiny of multiple government agencies and [...]

In Michael J. Fox's Shoes: Nike Will Raffle 'Back To The Future' Sneakers To Raise Parkinson's Dough — Video Michael J. Fox, photographed at the Forbes Philanthropy Summit in 2015. Michael J. Fox has a saying (okay, he's got a million of them) used to motivate employees at his eponymous foundation in its war against Parkinson's disease, which the 55-year-old actor has had for 26 years.
More Articles →
Oct 22, 2016

@8bitgenstein @wildlife who said anything about arbitrary price controls? Right now we just have arbitrary prices.

Oct 22, 2016

@8bitgenstein @wildlife doesn't look like it. Central thesis: insurers are ineffective at controlling cost.

Oct 22, 2016

@ddiamond this gives me so many conflicting emotions.

Oct 22, 2016

RT @BoutrousTed: I repeat: I will represent pro bono anyone #Trump sues for exercising their free speech rights. Many other lawyers…

Oct 22, 2016

RT @AndyBiotech: Actually at least 8 approvals from Medarex platform: Opdivo Yervoy Arzerra Darzalex Zinplava STELARA SIMPONI Ilaris

Oct 22, 2016

RT @davidkroll: Totally not cool that my @CVSHealth is still selling a homeopathic teething product associated with infant seizures.

Oct 22, 2016

@Wildbiftek @8bitgenstein bad, expensive drugs look to me like a better business than new, well-priced ones.

Oct 22, 2016

@Wildbiftek @8bitgenstein Yes. But that means costs should be skewed toward more innovative drugs. Not capturing $$$ for underperformers.

Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio